Posted by Michael Wonder on 27 Aug 2019
Akorn receives FDA approval for azelastine hydrochloride 0.15% nasal spray
26 August 2019 - Akorn today announced that it received a new Abbreviated new drug application approval from the U.S. FDA for azelastine hydrochloride 0.15% nasal spray.
The product is manufactured at Akorn’s Amityville, New York manufacturing facility.
